Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.

BACKGROUND Major randomized trials of fibrate therapy demonstrate an inverse relationship between on-treatment high-density lipoprotein cholesterol (HDL-C) increments and clinical outcome. We hypothesized that the degree of HDL-C response to bezafibrate is independently associated with subsequent long-term mortality. METHODS The risk of death at 16 years of follow-up among 3026 patients with coronary heart disease allocated to the original bezafibrate (n = 1509) and placebo (n = 1517) arms of the Bezafibrate Infarction Prevention (BIP) trial was related to HDL-C response to bezafibrate therapy, categorized as upper-tertile (>8 mg/dL) or lower-tertile (< or =8 mg/dL) on-treatment HDL-C change. RESULTS Multivariate analysis demonstrated that patients allocated to bezafibrate therapy experienced a significant 11% reduction (P = .06) in the risk of long-term mortality compared with placebo-allocated patients. Mortality reduction among bezafibrate-allocated patients was related to a significant 22% (P = .008) reduction in the risk of death in patients with an upper-tertile HDL-C response to therapy, whereas among patients with a lower HDL-C response, the risk of death was similar to that of the placebo group (hazard ratio, 0.95; P = .43). Accordingly, the cumulative probability of death at 16 years was significantly lower among bezafibrate-allocated patients with an upper-tertile HDL-C response (32.1%) compared with the placebo group (37.9%; P = .02), whereas patients with a lower HDL-C response to treatment displayed a mortality rate (36.8%) similar to the placebo group (P = .57). CONCLUSION Our findings suggest that HDL-C level-raising therapy with bezafibrate is associated with long-term mortality reduction that may be related to the degree of HDL-C response to treatment.

[1]  J. Liao HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2008, Current atherosclerosis reports.

[2]  U. Goldbourt,et al.  Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. , 2008, Journal of the American College of Cardiology.

[3]  P. Heidenreich,et al.  Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. , 2008, Journal of the American College of Cardiology.

[4]  A. Gotto,et al.  HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2007, The New England journal of medicine.

[5]  H. Drexel Reducing risk by raising HDL-cholesterol: the evidence , 2006 .

[6]  L. Tenkanen,et al.  Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. , 2006, Archives of internal medicine.

[7]  U. Goldbourt,et al.  Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial). , 2006, The American journal of cardiology.

[8]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[9]  E. Bruckert,et al.  High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients , 2005, Current medical research and opinion.

[10]  D. Tanné,et al.  Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. , 2005, Archives of internal medicine.

[11]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[12]  M. Pfeffer,et al.  Coronary Heart Disease in Patients With Low LDL-Cholesterol: Benefit of Pravastatin in Diabetics and Enhanced Role for HDL-Cholesterol and Triglycerides as Risk Factors , 2002, Circulation.

[13]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[14]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[15]  Loyd,et al.  SIMVASTATIN AND NIACIN , ANTIOXIDANT VITAMINS , OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE , 2001 .

[16]  Bezafibrate Infarction Prevention study Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[17]  Ames,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[18]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[19]  U. Goldbourt,et al.  Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). , 1993, The American journal of cardiology.

[20]  P. Allhoff,et al.  Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle Aged Men with Dyslipidemia , 1991 .

[21]  J. Huttunen,et al.  Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. , 1988, JAMA.

[22]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[23]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[24]  P. Wilson,et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.

[25]  J. Vollmar,et al.  Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia. , 1985, Atherosclerosis.

[26]  D. Grafnetter,et al.  A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. , 1978, British heart journal.